Skip to main content

UTI Suppressive and Prophylactic Therapy

Recurrent urinary tract infection (rUTI) — defined as ≥2 symptomatic, culture-confirmed UTIs in 6 months or ≥3 in 12 months — is one of the most common chronic problems in functional urology and urogynecology. The overarching goal of prophylaxis is to improve quality of life while minimizing antimicrobial exposure.[1][2] The AUA/CUA/SUFU 2022 guideline recommends a stepwise, individualized strategy that begins with non-antibiotic measures — vaginal estrogen in postmenopausal women, methenamine hippurate, cranberry, hydration — and reserves daily antibiotic prophylaxis for patients in whom non-antibiotic strategies have failed, with explicit acknowledgment that methenamine is non-inferior to daily antibiotics in head-to-head RCT evidence.[1][3]

Before initiating any prophylactic strategy, active infection must be eradicated and confirmed by a negative culture 1–2 weeks after treatment.[4]

For adjacent topics, see UTI treatment antibiotics, Non-antibiotic UTI prevention, and Recurrent UTI (clinical).

Stepwise prevention framework​

Multiple guidelines converge on the same escalation ladder — non-antibiotic first, antibiotic prophylaxis only after those fail.[1][5][6][7]

StepInterventions
1. Behavioral / non-pharmacologicIncreased fluid intake (≥1.5 L/day extra), postcoital voiding, constipation management, review of contraceptive methods (spermicide avoidance)
2. Non-antibiotic prophylaxisVaginal estrogen (first-line in postmenopausal women), methenamine hippurate, cranberry proanthocyanidins
3. Self-start / symptomatic therapyPre-prescribed treatment course for patients who can reliably self-diagnose
4. Antibiotic prophylaxisPost-coital single dose (if temporally related to intercourse) → continuous low-dose prophylaxis
5. Immunoprophylaxis (where available)OM-89, MV140, Urovac — not FDA-approved in the US

Non-antibiotic prophylaxis​

Vaginal estrogen — first-line in postmenopausal women​

Vaginal estrogen restores Lactobacillus colonization, lowers vaginal pH, and reduces uropathogen colonization — the mechanistic basis of GSM-driven rUTI. Available as vaginal cream, tablets / inserts (e.g., estradiol 10 µg tablets), and the estradiol ring. A meta-analysis showed a trend toward reduced recurrence (RR 0.42; 95% CI 0.16–1.10); local irritation occurs in 6–20% of women.[8]

Systemic estrogen should not be used for UTI prevention.[5] See GSM for the full treatment framework.

Methenamine hippurate — AUA-endorsed alternative to daily antibiotics​

Methenamine hippurate (1 g BID) is an antimicrobial-sparing urinary antiseptic that hydrolyzes to formaldehyde in acidic urine (pH <6). It is now supported by two major RCTs that together justify its AUA/CUA/SUFU 2022 endorsement.[1]

ALTAR trial (Harding 2022, BMJ, multicenter open-label non-inferiority RCT, n = 240 women with rUTI):[9][10]

  • Methenamine hippurate 1 g BID vs daily low-dose antibiotics (nitrofurantoin 50–100 mg, trimethoprim 100 mg, or cefalexin 250 mg) over 12 months
  • Incidence 1.38 vs 0.89 episodes/person-year — absolute difference 0.49, within the predefined non-inferiority margin of 1 UTI/person-year
  • Antibiotic resistance in E. coli from perineal swabs was significantly higher in the antibiotic arm (72% vs 56%; p = 0.05) during treatment
  • Conclusion: methenamine is non-inferior to daily low-dose antibiotics with a meaningfully better resistance profile

ImpresU trial (Heltveit-Olsen 2025, CMI, triple-blind placebo-controlled phase IV RCT, n = 289 women ≥70 y):[11]

  • 6-month course: methenamine reduced antibiotic-treated UTIs by ~25% (IRR 0.75; 95% CI 0.57–1.0; p = 0.049)
  • Rebound effect after discontinuation: UTI incidence rose in the methenamine group (IRR 1.7; p < 0.05) — suggesting prophylactic benefit is confined to the treatment period

Emerging caveat: the frmRAB operon can confer formaldehyde resistance in some E. coli strains; the clinical impact is under investigation.[12]

Cranberry products​

The WikiGuidelines 2024 consensus provides a clear recommendation for cranberry products containing ≥36 mg proanthocyanidins (PAC) to reduce rUTI in women, children, and people susceptible to UTI after interventions.[7] Meta-analysis: RR 0.53 (95% CI 0.33–0.83) for recurrence.[8] Evidence is insufficient in older adults, patients with bladder-emptying problems, and pregnancy.[7]

D-mannose — negative in the largest rigorous RCT​

D-mannose binds type-1 fimbriae and theoretically blocks E. coli adherence to the urothelium. Small trials suggested benefit, but the MERIT RCT (Hayward 2024, JAMA Intern Med, n = 598 women in primary care with rUTI) was negative: 51.0% of D-mannose patients vs 55.7% of placebo patients experienced a medically attended UTI over 6 months.[13] The authors explicitly concluded D-mannose should not be recommended to prevent future UTIs in this population.

Increased water intake​

One RCT showed that an additional 1.5 L of water daily reduced UTI episodes in healthy premenopausal women.[7] Low-risk, reasonable to recommend.

Probiotics​

Evidence for vaginal or oral Lactobacillus products is heterogeneous across strains, routes, and populations — no clear recommendation; may be considered alongside vaginal estrogen in postmenopausal women.[6][7]

Antibiotic prophylaxis​

Antibiotic prophylaxis should be reserved for women in whom non-antibiotic strategies have failed and who meet rUTI criteria.[1][2] A systematic review and meta-analysis of 11 placebo-controlled trials (Jent 2022) showed antibiotic prophylaxis reduces UTI risk by 85% (RR 0.15; 95% CI 0.08–0.29), with no significant efficacy difference among nitrofurantoin, TMP-SMX, and norfloxacin in head-to-head comparisons.[14]

Continuous prophylaxis​

Typically dosed once daily at bedtime, initially for a 6-month trial with planned reassessment; published data support safe continuous use for 2–5 years without consistently emergent resistance in some cohorts.[2][4]

AgentTypical continuous dosePractical notes
Nitrofurantoin50–100 mg nightlyPreferred first-line; avoid if CrCl <30 mL/min; long-term pulmonary and hepatic monitoring[1][2]
TMP-SMX40/200 mg nightly or 3×/weekAvoid when local resistance >20%; rash and GI AEs[1][2]
Trimethoprim (monotherapy)100 mg nightlyAlternative where TMP-SMX is not tolerated[4]
Cephalexin125–250 mg nightlyALTAR comparator; reasonable β-lactam option[9]
Fosfomycin3 g PO every 10 daysEmerging; limited prophylaxis trial data

Post-coital prophylaxis​

For women whose UTIs are temporally related to intercourse, a single dose taken before or after intercourse is as effective as continuous prophylaxis with lower total antibiotic exposure.[2][4][14]

AgentPost-coital dose
TMP-SMX40/200 mg or 80/400 mg single dose
Nitrofurantoin50–100 mg single dose
Cephalexin250 mg single dose
Ciprofloxacin125 mg single dose (reserve — class AEs)

Self-start (patient-initiated) therapy​

For women with ≤2 UTIs/year who can reliably self-diagnose, providing a pre-prescribed short antibiotic course to start at symptom onset is a validated strategy that avoids both daily prophylaxis and delays in care.[2][4]

Immunoprophylaxis​

None of these are FDA-approved in the US, but they are part of the international recurrent-UTI armamentarium.

  • OM-89 (Uro-Vaxom) — oral immunostimulant containing lyophilized E. coli lysate. Meta-analysis of 4 trials (n = 891) showed RR 0.61 (95% CI 0.48–0.78) for recurrence; good safety profile. Grade A recommendation in the Latin American rUTI consensus.[8][15]
  • MV140 (Uromune) — sublingual polybacterial whole-cell vaccine (E. coli, K. pneumoniae, P. vulgaris, E. faecalis). Prospective cohort in frail elderly women showed a 7- to 40-fold reduction in UTI episodes after a 3-month course; larger RCTs are in progress.[16]
  • Urovac — vaginal mucosal vaccine; RR 0.75 (95% CI 0.63–0.89) with booster-dependent efficacy.[17]
  • Systematic review (Aziminia 2019, 10 RCTs, n = 1,537): vaccines reduced rUTI vs placebo (RR 0.74; 95% CI 0.67–0.81), low-quality evidence with substantial heterogeneity.[17]

Special populations​

Pregnancy​

After treating a UTI in pregnancy in a woman with prior rUTI, ACOG 2023 states clinicians may consider initiating antimicrobial suppression for the remainder of pregnancy using a once-daily low dose of a susceptible agent; continuous or post-coital regimens are both acceptable. Evidence is limited.[18]

Kidney transplant recipients​

Routine TMP-SMX prophylaxis in the first 6 months (for Pneumocystis prevention) incidentally reduces UTI and ASB frequency. Non-antibiotic adjuncts — cranberry, methenamine, vaginal estrogen — may be layered on. Do not systematically treat asymptomatic bacteriuria in this population — it has no benefit and selects resistance.[19][20]

Spinal cord injury / neurogenic bladder​

Long-term antibiotic prophylaxis is generally unsuccessful and is discouraged because of resistance selection. Recurrent infection (≥3/year) should prompt reassessment of the voiding program, catheter strategy, and bladder pressures rather than empiric prophylaxis. Prophylaxis should be considered only case-by-case and with specialist input.[21]

Post-reconstruction / diversion patients​

  • Continent cutaneous diversions, neobladder, augmentation cystoplasty — colonization is expected; treat only symptomatic infection
  • Recurrent symptomatic UTI in diversion patients should trigger evaluation for stones, retained mucus, incomplete emptying, or obstructed efferent limb before escalating antibiotic strategy
  • IPP and AUS patients with symptomatic rUTI warrant aggressive treatment of each episode given device-infection consequences; long-term suppression is rarely first-line

Monitoring and duration​

  • Initial 6-month trial of prophylaxis is standard, with planned reassessment.[2][4]
  • Continuous prophylaxis has been used safely for 2–5 years without clear emergence of resistant organisms in some series.[4]
  • Prophylactic benefit is confined to the treatment period — UTI rates return toward baseline after discontinuation for both methenamine and antibiotics.[7][11]
  • Periodic reassessment of strategy — including de-escalation to non-antibiotic prophylaxis or symptomatic self-start therapy — is appropriate.[2]
  • Screen for emerging nitrofurantoin pulmonary / hepatic toxicity in patients on long-term suppression; audit TMP-SMX recipients for hyperkalemia and renal function.

Evidence Summary​

StrategyEvidence levelKey trial / guidelineNotes
rUTI guideline frameworkLevel 1AUA/CUA/SUFU 2022[1]Stepwise, non-antibiotic first; methenamine endorsed
Methenamine non-inferiority to antibioticsLevel 1ALTAR 2022 BMJ[9][10]; ImpresU 2025 CMI[11]Non-inferior; placebo-superior in older women
Antibiotic prophylaxis efficacyLevel 1Jent 2022 meta (11 RCTs)[14]85% reduction vs placebo
Vaginal estrogen in postmenopausal rUTILevel 2Beerepoot 2013 meta[8]Trend toward benefit; first-line non-antibiotic
Cranberry PAC ≥36 mgLevel 1WikiGuidelines 2024[7]Clear recommendation for selected populations
D-mannoseLevel 1MERIT RCT 2024[13]Negative in largest primary-care RCT
Hydration + 1.5 L/dayLevel 2WikiGuidelines 2024[7]Reasonable low-risk measure
Immunoprophylaxis (OM-89, MV140, Urovac)Level 2Aziminia 2019 SR[17]RR 0.74; low-quality evidence; not FDA-approved

Clinical Positioning​

  • Escalate non-antibiotic strategies first. Vaginal estrogen in postmenopausal women, methenamine hippurate 1 g BID, cranberry with ≥36 mg PAC, and hydration are the appropriate first moves — supported by AUA/CUA/SUFU, WikiGuidelines, and the ALTAR/ImpresU data.[1][7][9][11]
  • Methenamine is non-inferior to daily antibiotics for rUTI prevention, with a better resistance footprint. It belongs in the conversation for nearly every rUTI patient before daily antibiotics are started.[9][10]
  • D-mannose evidence no longer supports routine use. The 2024 JAMA Intern Med MERIT trial is the largest and most rigorous data point and is negative.[13]
  • For women with coitus-related rUTI, post-coital single-dose antibiotic is as effective as continuous prophylaxis with far less antibiotic exposure.[14]
  • Self-start therapy is the right strategy for patients with low-frequency rUTI who can reliably recognize symptoms — no daily pill, prompt treatment.[2]
  • Initial 6-month trial, then reassess. Extended courses (2–5 y) are acceptable in selected patients but require periodic review; benefit is largely confined to the treatment period.[4][11]
  • Nitrofurantoin and TMP-SMX are the workhorses; fluoroquinolones should not be first-line for prophylaxis given AE burden.[14]
  • Do not treat asymptomatic bacteriuria in transplant, SCI, diversion, or catheter patients outside the IDSA 2019 exceptions — it does not prevent symptomatic UTI and accelerates resistance.[19][21]
  • In neurogenic patients, fix the plumbing before writing a prophylactic script. Voiding dynamics, catheter technique, and storage pressures drive recurrence far more than empiric antibiotics do.[21]
  • Immunoprophylaxis is real but US-inaccessible. OM-89 and MV140 have plausible data; watch for FDA approval of next-generation products.[15][16][17]

See Also​

References​

1. Anger JT, Bixler BR, Holmes RS, et al. "Updates to recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline." J Urol. 2022;208(3):536–541. doi:10.1097/JU.0000000000002860

2. Hooton TM. "Uncomplicated urinary tract infection." N Engl J Med. 2012;366(11):1028–1037. doi:10.1056/NEJMcp1104429

3. Steinman MA. "Alternative treatments to selected medications in the 2023 American Geriatrics Society Beers Criteria." J Am Geriatr Soc. 2025;73(9):2657–2677. doi:10.1111/jgs.19500

4. Fihn SD. "Acute uncomplicated urinary tract infection in women." N Engl J Med. 2003;349(3):259–266. doi:10.1056/NEJMcp030027

5. Siddiqui NY, Bradley MS. "Updates in clinical management of recurrent urinary tract infections." Obstet Gynecol. 2025. doi:10.1097/AOG.0000000000006060

6. Smith AL, Brown J, Wyman JF, et al. "Treatment and prevention of recurrent lower urinary tract infections in women: a rapid review with practice recommendations." J Urol. 2018;200(6):1174–1191. doi:10.1016/j.juro.2018.04.088

7. Nelson Z, Aslan AT, Beahm NP, et al. "Guidelines for the prevention, diagnosis, and management of urinary tract infections in pediatrics and adults: a WikiGuidelines group consensus statement." JAMA Netw Open. 2024;7(11):e2444495. doi:10.1001/jamanetworkopen.2024.44495

8. Beerepoot MA, Geerlings SE, van Haarst EP, van Charante NM, ter Riet G. "Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials." J Urol. 2013;190(6):1981–1989. doi:10.1016/j.juro.2013.04.142

9. Harding C, Mossop H, Homer T, et al. "Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open-label, randomised, non-inferiority trial (ALTAR)." BMJ. 2022;376:e068229. doi:10.1136/bmj-2021-0068229

10. Harding C, Chadwick T, Homer T, et al. "Methenamine hippurate compared with antibiotic prophylaxis to prevent recurrent urinary tract infections in women: the ALTAR non-inferiority RCT." Health Technol Assess. 2022;26(23):1–172. doi:10.3310/QOIZ6538

11. Heltveit-Olsen SR, Arnljots ES, Sundvall PD, et al. "Methenamine hippurate as prophylaxis for recurrent urinary tract infections in older women — a triple-blind, randomised, placebo-controlled, phase IV trial (ImpresU)." Clin Microbiol Infect. 2025. doi:10.1016/j.cmi.2025.07.006

12. Hodgkinson NC, Al-Rubaye T, Reed TCP, et al. "Implications for methenamine hippurate use in recurrent urinary tract infection management: formaldehyde resistance and altered urinary composition." PLoS Pathog. 2026;22(3):e1014081. doi:10.1371/journal.ppat.1014081

13. Hayward G, Mort S, Hay AD, et al. "D-mannose for prevention of recurrent urinary tract infection among women: a randomized clinical trial (MERIT)." JAMA Intern Med. 2024;184(6):619–628. doi:10.1001/jamainternmed.2024.0264

14. Jent P, Berger J, Kuhn A, et al. "Antibiotics for preventing recurrent urinary tract infection: systematic review and meta-analysis." Open Forum Infect Dis. 2022;9(7):ofac327. doi:10.1093/ofid/ofac327

15. Haddad JM, Ubertazzi E, Cabrera OS, et al. "Latin American consensus on uncomplicated recurrent urinary tract infection — 2018." Int Urogynecol J. 2020;31(1):35–44. doi:10.1007/s00192-019-04079-5

16. Lorenzo-Gómez MF, Padilla-Fernández B, Flores-Fraile J, et al. "Impact of whole-cell bacterial immunoprophylaxis in the management of recurrent urinary tract infections in the frail elderly." Vaccine. 2021;39(42):6308–6314. doi:10.1016/j.vaccine.2021.08.093

17. Aziminia N, Hadjipavlou M, Philippou Y, et al. "Vaccines for the prevention of recurrent urinary tract infections: a systematic review." BJU Int. 2019;123(5):753–768. doi:10.1111/bju.14606

18. American College of Obstetricians and Gynecologists. "Urinary tract infections in pregnant individuals." Obstet Gynecol. 2023;142(2):435–445. doi:10.1097/AOG.0000000000005269

19. Nicolle LE, Gupta K, Bradley SF, et al. "Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America." Clin Infect Dis. 2019;68(10):e83–e110. doi:10.1093/cid/ciy1121

20. Apicella L, Vecchione N, Minelli G, et al. "Urinary tract infections in kidney transplant recipients: a narrative review." Transplant Proc. 2026. doi:10.1016/j.transproceed.2026.04.006

21. Milligan J, Goetz LL, Kennelly MJ. "A primary care provider's guide to management of neurogenic lower urinary tract dysfunction and urinary tract infection after spinal cord injury." Top Spinal Cord Inj Rehabil. 2020;26(2):108–115. doi:10.46292/sci2602-108